Victoria Socha

DocwireNews

Patients with type 2 diabetes mellitus and chronic kidney disease (CKD) face increased risk of progression of CKD and cardiovascular events. The risk is substantial despite treatment with renin-angiotensin system inhibitors and sodium-glucose cotransport 2 inhibitors. According to Alberto Ortiz, MD, and colleagues, there is preclinical and clinical evidence supporting the key role of mineralocorticoid receptor in cardiorenal injury in patients with type 2 diabetes.In Expert Review of Clinical Pharmacology [doi:10.1080/17512433.2023.2213888] the researchers provided an overview of the risk factors for severe adverse events related to hyperkalemia as well as management of serum potassium levels in patients with CKD and type 2 diabetes treated with finerenone.Finerenone is a selective and nonsteroidal mineralocorticoid receptor antagonist that has been shown in preclinical studies to reduce heart and kidney inflammation and fibrosis. Results of clinical trials have suggested that finerenone reduces progression of CKD and the risk of cardiovascular events in patients with CKD and type 2 diabetes. The incidence of adverse events was similar to that of placebo.The rate of study drug discontinuation was low (1.7% of the finerenone group and 0.6% of the placebo group). The risk of severe adverse events related to hyperkalemia was also low.The researchers said, &ldquo;As finerenone increases potassium levels in a predictable way, patients at risk of hyperkalemia can be identified early in clinical practice and monitored for an easy management. This will allow people with type 2 diabetes mellitus and CKD to safely benefit from improved cardiorenal outcomes.&rdquo;

Jordana Jampel

Successful HIV Viral Suppression With At-Home Administration

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Latest News

Potassium Management in CKD and Type 2 Diabetes Mellitus

Chronic Kidney Disease

Risk factors for severe adverse events related to hyperkalemia as well as management of serum potassium levels in patients with CKD and type 2 diabetes treated with finerenone.

Hyperkalemia Risk With Finerenone

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe